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Abstract
A new, simple, sensitive and rapid spectrofluorimetric method for the determination of piroxicam and propranolol in pharmaceutical formulations has been described. The method is based on the oxidation of piroxicam and propranolol with cerium (IV) to
produce cerium (III), whose fluorescence was monitored at 352 nm while excited at 255 nm. The variables affecting oxidation of
these drugs were studied and optimized. Under the experimental conditions, the calibration graphs were linear over the range of
0.02-3.0 and 0.02-2.4 mg/L, respectively, for piroxicam and propranolol. The limit of detection for piroxicam and propranolol was
0.006 and 0.008 mg/L, respectively, and the relative standard deviation of 5 replicate determinations of these drugs at 1.0 mg/L
concentration level was 1.65 and 1.79%, respectively. Good recoveries in the range of 95-108% were obtained for spiked samples.
The proposed methods were successfully applied to the determination of piroxicam and propranolol in commercial pharmaceutical formulations.
Key words: piroxicam, propranolol, spectrofluorimetry, cerium

Introduction
Pi roxicam [4 -hyd roxy-2-met hyl-n- (2-py r idyl) 2H-1, 2-benzothiazine-3-carboxamide-1, 1-dioxide] is
a non-steroidal anti-inf lammatory drug with analgesic
and anti-pyretic activities. Piroxicam exhibited a rapid
and effective response in the treatment of many diseases
such as rheumatoid arthritis, osteoarthritis, ankylosing
spondylitis, gout juvenile rheumatoid arthritis, musculoskeletal disorders, postpartum pain and sport injuries.
The most serious reported side effects are gastrointestinal effects, such as ulcer, bleeding ulcers, etc(1).
Propranolol (1-isopropylamino-3-(1-naphthyloxy)2-propranolol) is a β-adrenergic blocking drug that has
been widely applied to the treatment of cardiac arrhythmia, sinus tachycardia, angina pectoris and hypertension. It has also been suggested to use in numerous
conditions including dysfunction labour and anxiety (2).
Propranolol is also used in low activity sports, reducing
cardiac frequency, contraction force and coronary flow.
Therefore, it has been included in the list of forbidden
substances by the International Olympic Committee.
Accordingly, the development of rapid and direct monitoring strategy of propranolol calls for interest (3).
Several analytical methods have been proposed
for the determination of piroxicam in pharmaceuticals,
namely spectrophotometric (4-8), chromatographic(7-9) and
electrochemical techniques (10-12), with special attention
* Author for correspondence. Tel: +98-411-3372250;
Fax: +98-411-3344798; E-mail: a.bavili@tbzmed.ac.ir

to those using spectrofluorimetry(1,13-17).
Propranolol has been determined in pharmaceutical
preparations by a range of methods, such as f luorimetry(18-20), phosphorimetry(21,22), chemiluminescene (23,24),
spectrophotometry (25,26), atomic absorption (27,28), electrochemical (2) , chromatography (29) and electrophoresis (30). USP pharmacopoeia describes chromatographic
assay for the deter mination of both piroxicam and
propranolol(31).
As f luorescence spectrometry with great sensitivity and selectivity as well as relatively low cost for the
operation, is widely used in quantitative analysis of
pharmaceuticals, we propose here a simple and inexpensive spectrofluorimetric method for the determination of
piroxicam and propranolol in pharmaceutical preparations. The method involves the oxidation of piroxicam
or propranolol with Ce(IV) and subsequent monitoring
of the fluorescence of Ce(III) at 352 nm after excitation
at 255 nm.
H2SO4
Piroxicam or Propranolol + Ce(IV)
Ce(III)
(Fluorescent)

Materials and methods
I. Apparatus
A Shimadzu RF-5301 PC spectrof luorophotometer,
equipped with a 150 W Xenon lamp and 1.00 cm quartz
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II. Reagents
Five hundred mg/L solutions of piroxicam (from
Zahravi, Tabriz, Iran; purity of 99%) and propranolol (from
Darupakhsh, Tehran, Iran; purity of 99%) were prepared
by dissolving appropriate amount of drugs in 10.0-mL
ethanol and 0.5-mL NaOH or HCl (1.0 M), in the case of
piroxicam or propranolol, respectively, and diluting to 25
mL with water. These solutions were protected from the
light and kept at 4°C for two week. Working standard solutions were prepared by appropriate dilution of these stock
standard solutions. The Ce(IV) solution at concentration
of 2.5 mM was prepared from Ce(IV)-sulfate-tetrahydrat
(E-Merck) in 0.2 M sulphuric acid and was kept at 4°C for
two week. A 5.0 M H 2SO4 solution and 1.0 M NaOH or
HCl solutions were also prepared.
All other reagents were of analytical reagent grade
(E. Merck) and all solutions were prepared in doubly
distilled water.
III. Recommended Procedures for Calibration
Aliquots of 0.02-3.0 mL (or 0.02-2.4 mL) from 10
mg/L piroxicam (or propranolol) standard solution were
transferred into a series of 10-mL volumetric f lasks.
Point two (or 0.1) mL Ce(IV) and 1.0 mL H 2SO 4 solution were then added to each f lask successively. Each
f lask was made up to the volume with water and the
solutions were allowed to stand at room temperature for
10 min. The fluorescence intensity of each solution was
measured at 352 nm while excited at 255 nm against a
blank prepared similarly.
IV. Procedure for the Pharmaceutical Preparations
The contents of five capsules of piroxicam (Razak,
Tehran, Iran), each containing 10 mg piroxicam, were
transferred to a 100-mL volumetric flask and dissolved
in 15-mL ethanol and 2.0-mL NaOH solution. Then, the
volume was adjusted to the mark with water to obtain a
500 mg/L solution of piroxicam.
I n t he case of pi roxica m gel ( Ha k i m, Teh ra n,
Iran), containing 0.5 g piroxicam per 100 g gel, sample
containing 2.5 mg piroxicam was weighed into a 50-mL
beaker and dissolved in 15-mL ethanol and 2.0-mL
NaOH solution. It was then filtered into a 50-mL volumetric flask and diluted to the mark with water. Thus, a
50 mg/L solution of piroxicam was obtained.
In the case of propranolol tablets (Tolidaru, Tehran,
Iran), contents of ten tablets, each containing 10 mg
propranolol, were accurately weighed individually and
finely powdered. Powdered sample containing 5 mg
propranolol was weighed and placed into a 15-mL glass
tube, dissolved in 10-mL ethanol and 1.0-mL HCl solu-

tion and was vigorously shaken on a vortex mixer for 30
sec. The solution was then filtered and transferred into
a 100-mL volumetric f lask. The residue was washed
in enough ethanol and the solution was finally made up
to the mark with water. Thus, a 50 mg/L solution of
propranolol was obtained. These solutions were diluted
quantitatively to yield concentrations in the range of
working standard solution and then the piroxicam or
propranolol contents were determined by the procedures
proposed above.

Results and Discussion
Ce(IV) serves as an oxidizing agent for the determination of drugs by monitoring the fluorescence of the
reduced Ce(III) (32-35). Ce(III) is usually more f luorescent than formed product and therefore, measurement of
its f luorescence can be employed as a sensitive method
for the determination of certain drugs. In the present
work piroxicam or propranolol were oxidized by Ce(IV)
in sulphuric acid medium and the fluorescence intensity
of the produced Ce(III) was monitored at 352 ± 3 nm
after excitation at 255 ± 3 nm. Excitation and emission
spectra for piroxicam and propranolol systems are given
in Figures 1 and 2, respectively.
I. Effect of Ce(IV) Concentration
The effect of Ce(IV) concentration on the f luorescence intensity was evaluated in the range of 0.1 –
2.5×10 -4 M. In Figure 3, it was shown that Ce(IV) at
concentrations of 2.5 – 5.0×10 -5 and 1.25 – 2.5×10 -5 M
lead to the saturation signals in the case of piroxicam
and propranolol, respectively. At concentrations lower
than this range the f luorescence intensity dropped due
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Figure 1. Emission and excitation spectra: a1 & b1: emission and
excitation of Ce(III) in reagents blank; a2 & b2: emission and
excitation of Ce(III) after oxidation with 0.4 mg/L piroxicam
solution (prepared from piroxicam capsule); a3 & b3: emission
and excitation of Ce(III) after oxidation with 0.4 mg/L piroxicam
solution (prepared from piroxicam gel); a4 & b4: emission and
excitation of Ce(III) after oxidation with standard solution of
piroxicam (0.5 mg/L); 5.0×10 -5 M Ce(IV); 0.5 M H 2SO4.
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to insufficient Ce(IV) for oxidation. On the other hand,
higher concentrations of Ce(IV) was reported to probably quench the fluorescence thus decreasing the detected
intensity(32,33,35). An aliquot of 0.2 or 0.1 mL of Ce(IV)
(final concentration of 5.0 or 2.5×10 -5 M) was used for
the oxidation of piroxicam or propranolol, respectively.
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II. Effect of H2SO4 Concentration
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The effect of H 2SO 4 concentration on the f luorescence intensity was depicted in Figure 4. It was observed
that the f luorescence intensity remained approximately
constant at the studied concentration range. Hence, an
aliquot of 1.0 mL H 2SO 4 (final concentration of 0.5 M)
was taken as optimum for other experiments.
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Figure 2. Emission and excitation spectra: a1 & b1: emission and
excitation of Ce(III) in reagents blank; a2 & b2: emission and
excitation of Ce(III) after oxidation with 0.4 mg/L propranolol
solution (prepared from propranolol tablet); a3 & b3: emission
and excitation of Ce(III) after oxidation with standard solution of
propranolol (0.6 mg/L); 2.5×10 -5 M Ce(IV); 0.5 M H2SO4.
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Figure 4. Effect of H2SO4 concentration on the spectrofluorimetric
responses: 0.5 mg/L piroxicam or propranolol; 5.0×10 -5 or 2.5×10 -5
M Ce(IV) in the case of piroxicam or propranolol, respectively.

Figure 3. Effect of Ce(IV) concentration on the spectrofluorimetric
responses: 0.5 mg/L piroxicam or propranolol; 1.0 M H2SO4.
Table 1. Analytical characteristics of the methods
Analyte

Method
(Spectrofluorimetry)

Concentration
range (mg/L)

Slope

Intercept

r2

RSD
(%)

LOD
(mg/L)

Ref.

Piroxicam

Monitoring of Ce(III) fluorescence

0.02 – 3.0

276.8

-13.32

0.9976

1.65

0.006a

This work

Direct spectrofluorimetry

0.01–1.25

16.3

1.0

0.998 (r)

1.20

0.012

1

Indirect spectrofluorimetry

0.2 – 8.0

–

–

–

–

–

13

Europium sensitized fluorescence

100 – 2000 ppb

–

–

–

2 and 3

23.0 ppb

14

Solid-phase extraction and
room-temperature fluorimetry

0.03 – 0.2

42.3

1.02

0.993 (r)

–

0.010

15

Micelle-enhanced fluorescence

0.05 – 1.5

–

–

–

–

0.015

16

Spectrofluorimetry in the presence
of β-cyclodextrin

0.02 – 1.0

28.6

2.9

0.999 (r)

–

0.02

17

Propranolol Monitoring of Ce(III) fluorescence

0.02 – 2.4

269.9

-3.44

0.9969

1.79

0.008a

This work

0.4 – 18.0

–

–

–

–

13

Indirect spectrofluorimetry

a

Synchronous spectrofluorimetry

6 – 200 ppb

Fluorimetry (sequential injection
analysis)
Synchronous spectrofluorimetry

–
-3

-4

1.446×10

3.07×10

0.9997

1.50

1.9 ppb

18

0.0 – 4.0

4246.8

−44.9

> 0.999

2.35

0.02

19

0.02 – 1.0

–

–

–

–

–

20

Determined as three times the standard deviation of the blank signals.
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Table 2. Tolerance limits of interfering species in the determination of 1.0 mg/L of piroxicam or propranolol
Additive

Tolerance concentration
ratio (C/C)

%Recovery (n = 3)
In the case of piroxicam

%Recovery (n = 3)
In the case of propranolol

Magnesium stearate

120

101.2 ± 1.62

99.6 ± 1.72

Sucrose

100

98.7 ± 1.58

100.5 ± 1.81

Lactose

60

99.5 ± 1.64

98.4 ± 1.74

Glucose

50

98.8 ± 1.57

99.5 ± 1.83

Saccharose

50

98.5 ± 1.54

98.1 ± 1.76

Citric acid

10

97.6 ± 1.57

98.7 ± 1.77

Propylene glycol

2

102.3 ± 1.70

101.7 ± 1.79

Table 3. Determination of piroxicam and propranolol in pharmaceutical preparations
Piroxicam content*

Method
Piroxicam capsule (10 mg/capsule)
Piroxicam gel (0.5 g/100g)
Propranolol tablet (10 mg/tablet)

Tabulated t and

Proposed method

Direct spectrofluorimetric method

F values**

10.4 ± 0.17

10.2 ± 0.14

t = 1.57, F = 1.47

0.5 ± 0.01

–

10.3 ± 0.18

10.1 ± 0.15

t = 1.48, F = 1.44

*Average of three determinations ± standard deviation.
**Tabulated t and F values at p = 0.05 and n = 4 are 19 and 2.78, respectively(36).

III. Effect of Temperature and Time
The proposed methods involve the rapid reaction
between piroxicam or propranolol and Ce(IV) at ambient temperature without heating. Whereas, heating at
high temperatures for several minutes has been reported
in other methods for the determination of macrolide
antibiotics and psychoactive drugs (32,33). The effect of
equilibration time on f luorescence intensity was also
investigated and the results indicated that an equilibration time of 10 min is adequate to obtain the maximum
fluorescence intensity.
IV. Characteristics of the Method
The linear concentration range, relative standard
deviation (RSD) and the limit of detection (LOD), calculated as three times the standard deviation of the blank
signals, for piroxicam and propranolol are shown in
Table 1. The obtained LOD for piroxicam and propranolol was 0.006 and 0.008 mg/L, respectively. The RSD
for 5 replicate determinations of piroxicam and propranolol at 1.0 mg/L concentration level was 1.65 and 1.79%,

respectively. The figures of merit of our methods, which
were compared with other spectrof luorimetric methods
as shown in Table 1, are comparable or superior among
these methods.
V. Interference Study
In order to evaluate the possible analytical applications of the proposed method, the influence of frequently
encountered excipients and additives were studied by
analyzing sample solutions containing 1.0 mg/L of
piroxicam or propranolol with different amounts of
possible interferents. The tolerance limit was taken as
the concentration causing an error less than 5% in the
determination of the drug as shown in Table 2. Besides,
the obtained recovery indicated that no serious interference occurred from the classical additives tested.
VI. The Validation and Application of the Method
The proposed method was successfully applied to
the analysis of piroxicam or propranolol in commercial pharmaceutical preparations (Table 3). Statistical
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Table 4. Results of recoveries of commercial dosage form
Dosage form

Prepared solution

Piroxicam capsule

0.5 mg/L

Piroxicam gel

Propranolol tablet

Piroxicam or
propranolol
added (mg/L)

Piroxicam or
propranolol
found (mg/L)*

C.V%

E%

0.2

0.69 ± 0.01

1.45

-5

95

0.5

0.99 ± 0.02

2.02

-2

98

1.0

1.46 ± 0.02

1.37

-4

96

0.2

0.71 ± 0.01

1.41

+5

105

0.5

1.01 ± 0.02

1.98

+2

102

1.0

1.58 ± 0.03

1.89

+8

108

0.2

0.70 ± 0.01

1.43

0

100

0.5

1.04 ± 0.02

1.92

+8

108

1.0

1.53 ± 0.03

1.96

+3

103

Recovery (%)

0.5 mg/L

0.5 mg/L

*Average of three determinations ± standard deviation.

analysis of the obtained results was carried out at 95%
confidence interval and no significant difference was
observed with regard to the accuracy and precision.
The piroxicam or propranolol content measured by the
proposed methods was in excellent agreement with those
obtained by direct spectrofluorimetric methods (1,19).
The validity of this method was further assessed by
spike – recovery test on solutions prepared from piroxicam or propranolol formulations (Table 4) with recoveries ranging from 95% to 108%. The recovery, along
with the coincidence of excitation and emission spectra
of drug formulations to those of the standard solution of
piroxicam or propranolol (see Figure 1 or 2), indicated
that no significant matrix effect was observed in the
proposed procedure.

Conclusions
This report describes a validated spectrofluorimetric method for the assay of piroxicam and propranolol
without interference of common excipients. This is
recommended as a method for piroxicam and propranolol
testing either in bulk or the corresponding dosage forms
in routine quality control. The sensitivity is comparable
to the existing spectrofluorimetric methods for the determination of piroxicam and propranolol with wider linear
dynamic range (LDR) in most cases. In addition, the
LOD and LDR of this method are comparable or better
than those of other methods using Ce(IV) as oxidant for
pharmaceutical compounds (32-34). From the economic
point of view, the proposed method is simple, rapid and
inexpensive, and thus seems a good alternative to previously reported methods.
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